drug
as of 2026-07-01SCA-136
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Wyeth is now a wholly owned subsidiary of Pfizer
3 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Trials
3
Safety, PK and PD Study in Healthy Male Japanese Subjects
NCT00447941Phase 1Completed
Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female Subjects
NCT00458107Phase 1Completed
Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male Subjects
NCT00505973Phase 1Completed
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
trial
indication
indication
indication